MS
DMAC icon

Maven Securities’s DiaMedica Therapeutics DMAC Stock Holding History

Maven Securities’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-359,285
Closed -$1.47M – 639
2020
Q3 		$1.47M Buy
+359,285
New +$1.9M 0.12% 174

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Maven Securities's DMAC Position: Q4 2020 in Review

Maven Securities sold out of DiaMedica Therapeutics (DMAC) in Q4 2020, closing a stake of 359,285 shares — an estimated $1.47M sold.

Maven Securities first reported a position in DMAC in Q3 2020 and held it in 1 quarter. The position peaked at $1.47M in Q3 2020. 36 funds tracked by Wall St. Rank hold DMAC as of Q4 2020.

  • Maven Securities reported no remaining DiaMedica Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Maven Securities sold 359,285 DiaMedica Therapeutics shares in Q4 2020, an estimated $1.47M.
  • Maven Securities first reported a position in DiaMedica Therapeutics in Q3 2020 and held it in 1 quarter.
  • Maven Securities's DiaMedica Therapeutics position peaked at $1.47M in Q3 2020.
  • 36 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2020.

Based on Maven Securities's 13F filing for Q4 2020, filed 12 Feb 2021.